Oppenheimer raised the firm’s price target on Corbus Pharmaceuticals to $88 from $80 and keeps an Outperform rating on the shares after the company reported Q2 results, provided updates to the clinical timelines for both ‘913 and ‘601, and further guided on trial milestones for ‘701, including anticipated interim data early in 2025. Cash at end of Q2 was $147M bolstered by $36M in ATM proceeds in Q2, and another $29M in early Q3 reflected in the firm’s updated model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Shares Updated Corporate Presentation
- Corbus Pharmaceuticals Shares Operational Insights with SEC
- Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- CRBP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Affirm, Sprouts Farmers upgraded: Wall Street’s top analyst calls